NCT05643534: Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years |
|
|
| Recruiting | 3 | 180 | US | Tenapanor 50 MG, Tenapanor 25 mg bid, Placebo | Ardelyx | Irritable Bowel Syndrome With Constipation (IBS-C) | 12/25 | 12/25 | | |